Lightning Process -outcome measures study

Abstract

An earlier 2010 snapshot survey reported positive outcomes and high satisfaction and utility scores from participants attending the Lightning Process (LP). This identified a need for a further study using well validated data collection measures to more accurately evaluate the intervention. This interim report on that ongoing study (N = 205, 80% female, mean age 37.4, SD = 15.6 years, age range 9-73) adds to the evidence base by using well validated measures (RAND SF-36) to evaluate outcomes and collecting data at pre-course, at 6 weeks and 3 months to evaluate the durability of changes. Participants presented with a range of conditions, and all client diagnoses were provided by the clients along with the name of the diagnostician. The results find that the LP is making a significant positive impact, resulting in increased health status at 6 weeks, persisting at 3 months, and demonstrating improvements in all areas that were covered by the RAND SF36 questionnaire. It is hoped this interim report will add weight to future grant and funding applications for larger-scale Randomised Controlled Trials (RCT). The outcomes for the full report with 6 and 12 month data are currently being analysed.

Full text

!
Lightning Process - outcome measures study
Finch, F. 2013
Abstract: An earlier 2010 snapshot survey reported positive outcomes and high
satisfaction and utility scores from participants attending the Lightning Process (LP).
This identified a need for a further study using well validated data collection
measures to more accurately evaluate the intervention.
This interim report on that ongoing study (N = 205, 80% female, mean age 37.4, SD
= 15.6 years, age range 9-73) adds to the evidence base by using well validated
measures (RAND SF-36) to evaluate outcomes and collecting data at pre-course, at
6 weeks and 3 months to evaluate the durability of changes. Participants presented
with a range of conditions, and all client diagnoses were provided by the clients along
with the name of the diagnostician.
The results find that the LP is making a significant positive impact, resulting in
increased health status at 6 weeks, persisting at 3 months, and demonstrating
improvements in all areas that were covered by the RAND SF36 questionnaire. It is
hoped this interim report will add weight to future grant and funding applications for
larger-scale Randomised Controlled Trials (RCT). The outcomes for the full report
with 6 and 12 month data are currently being analysed.

!"#$%&"&#'()*+,--.''
(),/"0"&1)2'34567'89%+*0,-':1%1'
!"#$%&'&()
!"#"$%"&'("$)*+")',-./,)'*)012'30("'45'3")%012'67'8"9"8):';+"<%")%='>'?""@)='7'(41%A)B'?"+"'C4(#*%"&'%4'$1$8D)"'
%A"'E'&0("1)041)'45'%A"'!,-F'GH<7>I'J"$8%A'CA$12"='#AD)0C$8'5*1C%041012='+48"'80(0%$%041)'&*"'%4'#AD)0C$8'A"$8%A='+48"'
80(0%$%041)' &*"' %4' "(4%041$8' #+4K8"()=' "1"+2DL5$%02*"=' "(4%041$8' ?"88<K"012=' )4C0$8' 5*1C %041012=' #$01' $1&' 2"1"+$8'
A"$8%AM' N+""1A4*)"<N"0))"+' #4)%<A4C' C4++"C%041)' $1&'O415"++410'#4)%<A4C'C4(#$+0)41)'?"+"'$##80"&M'F")C+0#%09"'
G%$%0)%0C)'$+"'+"#4+%"&'$)'P"$1)'$1&'G%$1&$+&'F"90$%041)M'P0))012'&$%$'?$)'"QC8*&"&'5+4('%A"'$1$8D)0)M'
*#+,'-'.#",&()
,'%4%$8' 45' RST' #$+%0C0#$1%)' A$&' C4(#8"%"&' %A"' U02A%1012 ' ;+4C"))' 3 +$01012' ;+ 42+$(("M' P "$1' $2"' 45 ' #$+%0C0#$1%)' $%'
%0("'45' "1%+D' %4' %A"'#+42+$(("'?$)' 7VMW'D"$+)'45'$2"' 6GFXYTM>'D"$+)BM'3?"1%D' #"+C"1%'45'#$+%0C0#$1%)'?"+"'($8"'
6-XWYB' $1&' ZS[' ?"+"'5"($8"' 6-XY>W:' )""' H02*+"' YBM' ;+0($+D' )"85<+"#4+%"&' &0$214)")' $1&' +"$)41)' 54+' #+42+$(("'
$%%"1&$1C"'?"+"'#+"&4(01$1%8D'54+'5$%02*"<+"8$%"&')D1&+4(")')*CA'$)'PD$820C'\1C"#A$84(D"80%0)'4+']A+410C'H$%02*"'
GD1&+4("' 6>WMW[=' -XY7RBM' ,1Q0"%DLF"#+"))041' &0)4+&"+)' ?"+"' $8)4' C4((41=' ?0%A' YVMY[' 45' #$+%0C0#$1%)' 6-X7TB'
+"#4+%012' ,1Q0"%DLF"#+"))041M' RME[' 45' #$+%0C0#$1%)' +"#4+%"&' )*55"+ 012' 5+4(' P*8%0#8"' G C8"+4)0)' 6-X>B' $ 1&' $' 5*+%A"+'
RME['45'#$+%0C0#$1%)'+"#4+%"&'%A"'&0$214)0)'45'H0K+4(D$820$'6-X>BM'H*+%A"+'+"$)41)'54+'$%%"1&$1C"'?"+"'209"1')*CA'$)'
84?')"85<")%""('6RMW[='-XTB='CA+410C'#$01'6YMT[='-X7B='$&&0C%09"'&0)4+&"+)'6Y[='-XRB='.K)"))09"']4(#*8)09"'F0)4+&"+'
6SMT[='-XYB'4+'4%A"+L*1@14?1'&0$214)")'6VM7[='-XYTBM'F0$214)")'$+"'209"1'01'H02*+"'RM''
'
!"#$%&'()'-4M'45'#$+%0C0#$1%)'$CC4+&012'%4'2"1&"+M'
'

!"#$%&'()!"#$%&
'#()'*#+!+,-./)0#0!-/+!'#-0)/0!%)'!1,.2*/,/.!3')4#00!*'-,/,/.!(').'-55#!-**#/+-/4#
!
!"#$%&#'
6#(#-*#+! 7#-08'#0! 9:;<90! 02)=#+! -! 0,./,%,4-/*! +,%%#'#/4#! ,/! -$$! 08>
?#0*,/.@!A#-$*2! 42-/.#! B!
BCDEFGHCFIJCKD!
+8#! *)! 32L0,4-$! A#-$*2! B!
BMD! CNNGHONJ FCD!
*PJFFFCGQ! R/#'.LS%-*,.8#! B!
BMD! CIMGHMIJEED!
%8/4*,)/,/.! B!BMD! CMMGHTIJUND! *
PJFFFCGQ! 3-,/! B
*
PJFFFCGJ!?2,0!,/+,4-*#0!*2#!1,.2*/,/.!3')4#00!+)#0!,5(-4*!8()/!-$$!+,5#/0,)/0!)%!2#-$*2!*#0*#+!>L!*2#!"V
9$$! 08>&04-$#0! )%! *2#! 69:W! "V&
IT! 02)=#+! 0,./,%,4-/*! ,5(')X#5#/*0! -4')00! ?,5#! )%! ?#0*,/.D! =,*2! 2#-$*2! 0*-*80!
,5(')X,/.!%')5!('#&
1,.2*/,/.!3')4#00!*)!*2#!T!=##Y!%)$$)=
+,5#/0,)/0! B*P
JFFFCG! #Z4#(*! ,/! *2#! *=)! #5)*,)/
-/+!R5)*,)/-$!=#$$&
>#,/.J!!?2#!5-[)',*L!)%!*2#!08>
02)=#+! /)! %8'*2#'! 0,./,%,4-/*! ,5(')X#5#/*D! ,/+,
*2#'#%)'#! 2#-$*2! 0*-*80! -*! T! =##Y0! =-0! 5-,/*-,/#+! -*! I! 5)/*20J! A)=#X#'! %)'! *2#! #/#'.LS%-*,.8#! +,5#/0,)/D!
(-'*,4,(-/*0! 02)=#+! 4)/0#48*,X#! ,/4'#-0#0! ,/! *2#,'! #/#'.L! $#X#$0D! #Z2,>,*#+! *2')8.2! -! 0,./,%,
('#&*#0*!-/+!T!=##Y0!B*
PJFFFCG!-/+!-.-,/!%')5!T!=##Y0!*)!I!5)/*20!B
'#()'*#+!+,-./)0#0!-/+!'#-0)/0!%)'!1,.2*/,/.!3')4#00!*'-,/,/.!(').'-55#!-**#/+-/4#
6#(#-*#+! 7#-08'#0! 9:;<90! 02)=#+! -! 0,./,%,4-/*! +,%%#'#/4#! ,/! -$$! 08>
&
04-$#0! )%! *2#! 69:W! "V
BCDEFGHCFIJCKD!
*PJFFFCGQ!32L0,4-$! V8/4*,)/,/.!B!
BMD! CNTGHKMJNOD!
BMD! CNNGHONJ FCD!
*
PJFFFCGQ! 6)$#! $,5,*-*,)/0!+8#! *)! #5)*,)/-$! (')>$#50!B
BMD! CIMGHMIJEED!
*PJFFFCGQ! R5)*,)/-$! =#$$&>#,/.! B!BM
D! CNNGHCIJMKD!
PJFFFCGQ! 3-,/! B
!BMD! CNUGHIKJNCD! *
PJFFFCGQ! -/+! \#/#'-$! A#-$*2! B
PJFFFCGJ!?2,0!,/+,4-*#0!*2#!1,.2*/,/.!3')4#00!+)#0!,5(-4*!8()/!-$$!+,5#/0,)/0!)%!2#-$*2!*#0*#+!>L!*2#!"V
IT! 02)=#+! 0,./,%,4-/*! ,5(')X#5#/*0! -4')00! ?,5#! )%! ?#0*,/.D! =,*2! 2#-$*2! 0*-*80!
1,.2*/,/.!3')4#00!*)!*2#!T!=##Y!%)$$)=
&8(!B*
PJFFFCGJ!]5(')X#5#/*0!(#'0,0*#+!-*!I!5)/*20!%)'!-$$!
JFFFCG! #Z4#(*! ,/! *2#! *=)! #5)*,)/
&
'#$-*#+! +,5#/0,)/0@! 6)$#! $,5,*-*,)/0! +8#! *)! #5)*,)/-$! (')>$#50!
>#,/.J!!?2#!5-[)',*L!)%!*2#!08>
&
04-$#0!02)=#+!*2-*!2#-$*2!0*-*80!>#*=##/!T!=##Y0!-/+!I!5)/*20!
02)=#+! /)! %8'*2#'! 0,./,%,4-/*! ,5(')X#5#/*D! ,/+,
4-*,/.! *2-*! ,5(')X#5#/*0! ($-*#-8#+! +8',/.! *2,0! (#',)+! -/+!
*2#'#%)'#! 2#-$*2! 0*-*80! -*! T! =##Y0! =-0! 5-,/*-,/#+! -*! I! 5)/*20J! A)=#X#'! %)'! *2#! #/#'.LS%-*,.8#! +,5#/0,)/D!
(-'*,4,(-/*0! 02)=#+! 4)/0#48*,X#! ,/4'#-0#0! ,/! *2#,'! #/#'.L! $#X#$0D! #Z2,>,*#+! *2')8.2! -! 0,./,%,
PJFFFCG!-/+!-.-,/!%')5!T!=##Y0!*)!I!5)/*20!B
*
PJFOQ!0##!V,.8'#!IGJ
!
'#()'*#+!+,-./)0#0!-/+!'#-0)/0!%)'!1,.2*/,/.!3')4#00!*'-,/,/.!(').'-55#!-**#/+-/4#
!
04-$#0! )%! *2#! 69:W! "V
&IT! -4')00! ?,5#! )%!
BMD! CNTGHKMJNOD!
*PJFFFCGQ!6)$#! $,5,*-*,)/0!
PJFFFCGQ! 6)$#! $,5,*-*,)/0!+8#! *)! #5)*,)/-$! (')>$#50!B
!BMD! CNTGHIMJT MD!
D! CNNGHCIJMKD!
*PJFFFCGQ! ")4,-$!
PJFFFCGQ! -/+! \#/#'-$! A#-$*2! B
!BMD! CMUGHNCJEOD!
PJFFFCGJ!?2,0!,/+,4-*#0!*2#!1,.2*/,/.!3')4#00!+)#0!,5(-4*!8()/!-$$!+,5#/0,)/0!)%!2#-$*2!*#0*#+!>L!*2#!"V
&ITJ!
IT! 02)=#+! 0,./,%,4-/*! ,5(')X#5#/*0! -4')00! ?,5#! )%! ?#0*,/.D! =,*2! 2#-$*2! 0*-*80!
PJFFFCGJ!]5(')X#5#/*0!(#'0,0*#+!-*!I!5)/*20!%)'!-$$!
'#$-*#+! +,5#/0,)/0@! 6)$#! $,5,*-*,)/0! +8#! *)! #5)*,)/-$! (')>$#50!
04-$#0!02)=#+!*2-*!2#-$*2!0*-*80!>#*=##/!T!=##Y0!-/+!I!5)/*20!
4-*,/.! *2-*! ,5(')X#5#/*0! ($-*#-8#+! +8',/.! *2,0! (#',)+! -/+!
*2#'#%)'#! 2#-$*2! 0*-*80! -*! T! =##Y0! =-0! 5-,/*-,/#+! -*! I! 5)/*20J! A)=#X#'! %)'! *2#! #/#'.LS%-*,.8#! +,5#/0,)/D!
(-'*,4,(-/*0! 02)=#+! 4)/0#48*,X#! ,/4'#-0#0! ,/! *2#,'! #/#'.L! $#X#$0D! #Z2,>,*#+! *2')8.2! -! 0,./,%,
4-/*!,/4'#-0#!>#*=##/!
PJFOQ!0##!V,.8'#!IGJ
!

We are pleased that this preliminary data supports the anecdotal evidence we receive on a
daily basis – ‘with the energy/fatigue dimension, participants showed consecutive increases
in their energy levels, exhibited through a significant increase between pre-test and 6 weeks
(p<.0001) and again from 6 weeks to 3 months (p<.05).’ The indications are that the LP is
making a significant positive impact, resulting in increased health status at 6 weeks,
persisting at 3 months, and demonstrating improvements in all areas that were covered by
the RAND SF36 questionnaire.
In two of the nine measured areas (the emotion-related dimensions) there was a significant
improvement on the baseline data, followed by a slight decrease, but with the scores at three
months still being significantly improved from the original baseline.
This interim data is useful information for the Lightning Process, supporting our findings to
date and highlighting areas to learn from. In light of this we are considering what measures
of additional support we can offer to clients, as required, to maintain and build on the
changes that are made following attendance of a Lightning Process seminar.
Full anonymised data is available on request.
!"#$%&'(&!"#$%&'(&)"*#(+(&#(&$#*,-%*#./0#$+1"#*-,*(2"*345!*67089:*5;:*!+(+*,-%*9*+<=*>?*@-<(2#*&#*$.%%"<(1A*&<*$-11"$(&-<:*
!
"#$
%
&"
!
'!($$)*
!
+!,-./0*
!
'!,-./0*
!
12!,-./0*
!
!
!
3
!
45
!
3
!
45
!
3
!
45
!
3
!
45
!
3
!
45
!
!
"
6$78/0!907.:$
!
))*+,
&
-'*.+
&
/'*0-
&
-/*+,
&
/-*+.
&
-/*+-
&
&
&
&
&
*111'
&
"0;*<=78!>?.=/<-.<.:
!
+2*/2
&
)/*)+
&
0,*-.
&
)'*.)
&
0+*,/
&
'.*-,
&
&
&
&
&
*111'
&
"0;*<=78!@-8$!&<,</7/<-.*
!
)'*+0
&
-/*''
&
2+*1/
&
-0*'-
&
2+*1/
&
-.*2.
&
&
&
&
&
*111'
&
A,-/<-.78!@-8$!&<,</7/<-.*
!
,.*')
&
,,*)-
&
0,*)-
&
).*-'
&
0'*.0
&
-'*/.
&
&
&
&
&
*111'
&
A.$#:;B>7/<:?$
!
--*+0
&
)2*''
&
2-*,-
&
'0*//
&
0,*/0
&
20*21
&
&
&
&
&
*111'
&
A,-/<-.78!C$88
%
D$<.:
!
2,*)/
&
'-*..
&
0,*..
&
-2*+2
&
/+*2)
&
',*,'
&
&
&
&
&
*111'
&
4-=<78!>?.=/<-.<.:
!
+'*+,
&
).*'-
&
0/*.,
&
'2*+-
&
0+*.2
&
)1*0/
&
&
&
&
&
*111'
&
"7<.
!
,'*,1
&
-'*1/
&
20*21
&
-1*.,
&
/,*11
&
).*/0
&
&
&
&
&
*111'
&
E$.$#78!6$78/0
!
,.*.)
&
'0*20
&
/'*'+
&
'.*/)
&
20*0+
&
)1*).
&
&
&
&
&
*111'
&
!
!
!
!
!"#$%&'()!"#$%&'(#()*+!,)!-(./*-!+*.*0+!&)!*-(!+012+3./(+!&4!*-(!5678!9:2;<=!
>
?>
@>
;>
A>
B>
<>
C>
D>
E>
?>>
F%(2GF <!H((I+ ;!#&)*-+
!"#$%&'(%#%)*'+,-
./0"'12'."*%/34
J(./*-!K-.)L(
F-M+,3./!:0)3*,&),)L
F-M+,3./!5&/(!G,#,*.*,&)+
N#&*,&)./!5&/(!
G,#,*.*,&)+
N)(%LMO:.*,L0(
N#&*,&)./!P(//21(,)L
9&3,./!:0)3*,&),)L